Refractory chronic migraine: long-term follow-up using a refractory rating scale

Area of Science:

• Neurology
• Pain Medicine
• Quality of Life Research

Background:

• Refractory chronic migraine (RCM) significantly impacts patients' quality of life (QOL) and daily functioning.
• Current clinical practice lacks standardized severity categorization for RCM, hindering targeted treatment and research.
• A 10-year longitudinal study is crucial to understand the long-term clinical course and treatment efficacy in RCM.

Purpose of the Study:

• To develop and validate a novel severity rating scale for Refractory Chronic Migraine (RCM).
• To assess the 10-year clinical course of RCM patients categorized by severity.
• To evaluate the impact of RCM severity on pain levels and quality of life (QOL) over time.

Main Methods:

• A cohort of 129 RCM patients (ages 19-72) was assessed over 10 years using a unique RCM severity rating scale (2-10).
• Pain intensity and QOL were measured at baseline and throughout the 10-year study period.
• Medication utilization, including opioids, triptans, butalbital, onabotulinumtoxinA, and stimulants, was recorded.

Main Results:

• Over 10 years, 73% of RCM patients experienced a ≥30% reduction in pain.
• Pain improved by 45% in mild, 42% in moderate, and 36% in severe RCM groups.
• QOL improved by 35% in mild, 32% in moderate, and 33% in severe RCM groups, with severe cases consistently showing poorer outcomes.

Conclusions:

• A severity scale effectively categorizes RCM patients, aiding clinical and research efforts.
• While pain and QOL improve across all RCM severity levels, severe cases remain significantly impaired.
• Opioids and frequent triptans were the most commonly used medications, highlighting current treatment trends in RCM.